Aldoxorubicin for the treatment of advanced soft tissue sarcoma

Bibliography

• JRToro, LBTravis, HJWu, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: An analysis of 26,758 cases. Int J Cancer 2006;119(12):2922-30
   PubMed Web of Science ®Google Scholar
• CWibmer, ALeithner, NZielonke, et al. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol 2010;21(5):1106-11
   PubMedGoogle Scholar
• LADoyle. Sarcoma classification: an update based on the 2013 World health organization classification of tumors of soft tissue and bone. Cancer 2014;120(12):1763-74
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & figures 2014. American Cancer Society; Atlanta: 2014
   Google Scholar
• National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER stat fact sheets: soft tissue including heart cancer. Available from: http://seer.cancer.gov/statfacts/html/soft.html [Last accessed 4 June 2014]
   Google Scholar
• CFCollin, CFriedrich, JGodbold, et al. Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. Semin Surg Oncol 1988;4(1):30-7
   PubMedGoogle Scholar
• VLe Doussal, JMCoindre, ALeroux, et al. Prognostic factors for patients with localized primary malignant fibrous histiocytoma: a multicenter study of 216 patients with multivariate analysis. Cancer 1996;77:1823-30
   PubMed Web of Science ®Google Scholar
• QTLe, KKFu, SKroll, et al. Prognostic factors in adult soft-tissue sarcomas of the head and neck. Int J Radiat Oncol Biol Phys 1997;37:975-84
   PubMedGoogle Scholar
• SVraa, JKeller, OSNielsen, et al. Prognostic factors in soft tissue sarcomas: the Aarhus experience. Eur J Cancer 1998;34:1876-82
   PubMedGoogle Scholar
• CDFletcher, KKUnni, FEMertens. World health organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press; Lyon, France: 2002
   Google Scholar
• TBrown, CYoung, LRushton, et al. Occupational cancer in britain. remaining cancer sites: brain, bone, soft tissue sarcoma and thyroid. Br J Cancer 2012;107(Suppl 1):S85-91
   Google Scholar
• FLevi, LRandimbison, MMaspoli-Conconi, et al. Incidence of second sarcomas: a cancer registry-based study. Cancer Causes Control 2014;25:473-7
   PubMedGoogle Scholar
• FLWong, JDBoiceJr, DHAbramson, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262-7
   PubMed Web of Science ®Google Scholar
• EAEngels, RJBiggar, VAMarshall, et al. Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS 2003;17:1847-51
   PubMed Web of Science ®Google Scholar
• IFPollack, JJMulvihill. Neurofibromatosis 1 and 2. Brain Pathol 1997;7:823-36
   PubMedGoogle Scholar
• FPLi, JFFraumeniJr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: soft tissue sarcoma. Version 2. 2014. Available from: http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf [Last accessed 10 June 2014]
   Google Scholar
• SSleijfer, CSeynaeve, JVerweij. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005;10:833-41
   PubMed Web of Science ®Google Scholar
• ECBorden, DAAmato, JHEdmonson, et al. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 1990;66:862-7
   PubMed Web of Science ®Google Scholar
• PChang, PHWiernik. Combination chemotherapy with adriamycin and streptozotocin. I. Clinical results in patients with advanced sarcoma. Clin Pharmacol Ther 1976;20:605-10
   PubMed Web of Science ®Google Scholar
• JHEdmonson, LMRyan, RHBlum, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-75
   PubMed Web of Science ®Google Scholar
• HBMuss, BBundy, PJDiSaia, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a Phase III trial of the Gynecologic Oncology Group). Cancer 1985;55:1648-53
   PubMed Web of Science ®Google Scholar
• GAOmura, FJMajor, JABlessing, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983;52:626-32
   PubMed Web of Science ®Google Scholar
• ASantoro, TTursz, HMouridsen, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 1995;13:1537-45
   PubMed Web of Science ®Google Scholar
• DASchoenfeld, CRosenbaum, JHorton, et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 1982;50:2757-62
   PubMed Web of Science ®Google Scholar
• IJudson, JARadford, MHarris, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2001;37:870-7
   PubMed Web of Science ®Google Scholar
• IJudson, JVerweij, HGelderblom, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled Phase III trial. Lancet Oncol 2014;15:415-23
   PubMed Web of Science ®Google Scholar
• EALefrak, JPitha, SRosenheim, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14
   PubMed Web of Science ®Google Scholar
• DDVon Hoff, MWLayard, PBasa, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-17
   PubMed Web of Science ®Google Scholar
• SELipshultz, SDColan, RDGelber, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808-15
   PubMed Web of Science ®Google Scholar
• SELipshultz, SRLipsitz, SMMone, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738-43
   PubMed Web of Science ®Google Scholar
• TSafra. Cardiac safety of liposomal anthracyclines. Oncologist 2003;8(Suppl 2):17-24
   PubMed Web of Science ®Google Scholar
• JVerweij, LHBaker. Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. Eur J Cancer 2010;46:863-8
   PubMed Web of Science ®Google Scholar
• CForscher, MMita, RFiglin. Targeted therapy for sarcomas. Biologics 2014;8:91-105
   PubMedGoogle Scholar
• WJGradishar, STjulandin, NDavidson, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803
   PubMed Web of Science ®Google Scholar
• MASocinski, IBondarenko, NAKaraseva, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a Phase III trial. J Clin Oncol 2012;30:2055-62
   PubMed Web of Science ®Google Scholar
• DDVon Hoff, TErvin, FPArena, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703
   PubMed Web of Science ®Google Scholar
• FKratz, AWarnecke, KScheuermann, et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002;45:5523-33
   PubMed Web of Science ®Google Scholar
• FKratz. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83
   PubMed Web of Science ®Google Scholar
• GStehle, HSinn, AWunder, et al. Plasma protein (albumin) catabolism by the tumor itself–implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol 1997;26:77-100
   PubMed Web of Science ®Google Scholar
• HMaeda, JWu, TSawa, et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84
   PubMed Web of Science ®Google Scholar
• DLebrecht, AGeist, UPKetelsen, et al. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 2007;120:927-34
   PubMed Web of Science ®Google Scholar
• CUnger, BHaring, MMedinger, et al. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin. Clin Cancer Res 2007;13:4858-66
   PubMed Web of Science ®Google Scholar
• MMMita, RBNatale, EMWolin, et al. Pharmacokinetic study of aldoxorubicin in patients with solid tumors. Invest New Drugs 2014. [Epub ahead of print]
   Google Scholar
• SPChawla, VSChua, AFHendifar, et al. A Phase IB/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer 2014. [Epub ahead of print]
   Google Scholar
• SPChawla, ZPapai, KSankhala, et al. Randomized Phase IIb trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas. J Clin Oncol 2014;32
   PubMedGoogle Scholar
• TJSmith, JKhatcheressian, GHLyman, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
   PubMed Web of Science ®Google Scholar
• BElsadek, FKratz. Impact of albumin on drug delivery–new applications on the horizon. J Control Release 2012;157:4-28
   PubMed Web of Science ®Google Scholar
• SSGhosh, PMKao, AWMcCue, et al. Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes. Bioconjug Chem 1990;1:71-6
   PubMed Web of Science ®Google Scholar